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Abstract 
Background 
Benzo[a]pyrene (BaP) is a widespread environmental genotoxic carcinogen that damages DNA by 
forming adducts. This damage along with activation of the aryl hydrocarbon receptor (AHR) induces 
complex transcriptional responses in cells. To investigate whether human cells are more susceptible to 
BaP in a particular phase of the cell cycle, synchronised breast carcinoma MCF-7 cells were exposed 
to BaP. Cell cycle progression was analysed by flow cytometry, DNA adduct formation was assessed 
by 32P-postlabeling analysis, microarrays of 44K human genome-wide oligos and RT-PCR were used 
to detect gene expression (mRNA) changes and Western blotting was performed to determine the 
expression of some proteins, including cytochrome P450 (CYP) 1A1 and CYP1B1, which are 
involved in BaP metabolism.  
Results 
Following BaP exposure, cells evaded G1 arrest and accumulated in S-phase. Higher levels of DNA 
damage occurred in S- and G2/M- compared with G0/G1-enriched cultures. Genes that were found to 
have altered expression included those involved in xenobiotic metabolism, apoptosis, cell cycle 
regulation and DNA repair. Gene ontology and pathway analysis showed the involvement of various 
signalling pathways in response to BaP exposure, such as the Catenin/Wnt pathway in G1, the ERK 
pathway in G1 and S, the Nrf2 pathway in S and G2/M and the Akt pathway in G2/M. An important 
finding was that higher levels of DNA damage in S- and G2/M-enriched cultures correlated with 
higher levels of CYP1A1 and CYP1B1 mRNA and proteins. Moreover, exposure of synchronised 
MCF-7 cells to BaP-7,8-diol-9,10-epoxide (BPDE), the ultimate carcinogenic metabolite of BaP, did 
not result in significant changes in DNA adduct levels at different phases of the cell cycle.  
Conclusions 
 This study characterised the complex gene response to BaP in MCF-7 cells and revealed a strong 
correlation between the varying efficiency of BaP metabolism and DNA damage in different phases of 
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the cell cycle. Our results suggest that growth kinetics within a target-cell population may be 
important determinants of susceptibility and response to a genotoxic agent. 
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Background 
Chemical carcinogens that act by a genotoxic mechanism exert their biological effects through 
damaging DNA. This damage can be manifested in several forms, including single or double strand 
breaks, apurinic sites and covalent modification of the bases. Some chemical carcinogens such as 
benzo[a]pyrene (BaP), which is a representative of the class of polycyclic aromatic hydrocarbons 
(PAHs), are thought to cause cancer through covalent binding of their reactive metabolites to DNA, 
forming DNA adducts [1-3]. BaP-7,8-diol-9,10-epoxides (BPDE), the ultimate carcinogenic 
metabolites of BaP, react predominantly with the N2 position of guanine residues and to a lesser extent 
with the N6 position of adenine residues in DNA [4]. 
In mammalian cells BaP binds to the aryl hydrocarbon receptor (AHR), which is a cytosolic 
ligand-activated transcription factor that functions as a sensor of extracellular signals and 
environmental stresses affecting cell growth and development. AHR controls the expression of genes 
coding for xenobiotic-metabolising enzymes such as cytochrome P450s (CYPs), UDP-
glucuronosyltransferase UGT1A6, NAD(P)H:quinone oxidoreductase-1 (NQO1), aldehyde 
dehydrogenase (ALDH3A1), and several glutathione-S-transferases [5]. It is also involved in 
regulation of development and in the control of circadian rhythms, neurogenesis and stress response to 
hypoxia [6].  
More recently it has also become evident that AHR has another function, namely in controlling 
cell cycle progression. For instance, high-affinity AHR ligands, such as some PAHs, cause a wide 
range of cell-cycle perturbations, including G0/G1 arrest or its evasion (the stealth property) [7], G2/M 
arrest, S-phase accumulation, diminished capacity for DNA replication and inhibition of cell 
proliferation [8]. These perturbations have been documented in several gene expression profiling 
studies. Previously we have used microarray technology to analyse the transcriptomes of several 
human cell lines exposed to BaP [9, 10]. Altered expression of a number of genes involved in cell 
cycle regulation were identified, including CDKN1A, MAK, BTG2, CCNG1 and E2F6. Other studies 
have shown that up-regulated AHR-dependent activation of CYP1A1 following BaP exposure may be 
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dependent on the cell-cycle phase [11-13], suggesting that the phase of the cell cycle may be critical to 
some of the effects of BaP on human cells. 
In this study, we investigated whether cells are more susceptible to a genotoxic carcinogen, 
namely BaP, at particular phases of the cell cycle and, if so, to elucidate the processes involved. DNA 
microarrays were used to examine changes in gene expression throughout the cell cycle in 
synchronised human breast carcinoma MCF-7 cells following exposure to non-cytotoxic 
concentrations of BaP. Cell cycle phase-specific changes in gene expression profiles resulting from 
carcinogen exposure have identified novel genes and pathways potentially involved in the 
carcinogenic process. To strengthen the process of identifying target genes, gene expression data were 
compared to other biological parameters, including DNA adduct formation, determined by 32P-
postlabelling analysis, and cell cycle progression, measured by FACS analysis. 
 
Results 
Cell cycle progression 
In initial experiments, the optimum time of treatment with BaP was determined to be 12 h. This gave 
sufficient time for cells to metabolise BaP to DNA-binding reactive intermediates, but minimised the 
extent to which untreated synchronised cells altered their cell-cycle phase composition. In the case of 
G0/G1 enrichment, cells will start exiting the quiescent state (G0) and entering G1 soon after adding 
the serum back to the medium. Thus, from now on, these cells are referred to as G1-enriched. In 
previous work, the treatment concentration of 2.5 µM was found to induce DNA adduct formation in 
MCF-7 cells within a linear dose-response range [9]. 
G1-enriched cultures (serum deprivation for 48 h) did not differ significantly in the proportions 
of cells in different phases after treatment for 12 h with BaP compared with DMSO-treated controls 
(Figure 1A and Additional file 1A). Cells were progressing through the cell cycle and started entering 
S and G2/M phases by the end of the treatment.  We did not observe a G1 arrest after BaP treatment.  
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Exposure of S-enriched cultures (18 h after 48 h of serum deprivation) to BaP evoked dramatic 
alterations in cell cycle distribution with an increase of the fraction of cells in S-phase (59.6 vs 32.4, 
P<0.001; Figure 1B and Additional file 1B). The percentage of cells in G2/M-phase was significantly 
lower than in control cultures (P<0.001).  
Similarly, BaP treatment of G2/M-enriched cultures (24 h treatment with 1 µg/mL aphidicolin 
followed by 12 h 0.25 µM colchicine)  increased the proportion of cells in S-phase (17.6 vs 11.2, 
P=0.0045; Figure 1C and Additional file 1C).  
 
DNA damage in synchronised MCF-7 cells 
BaP-DNA adduct formation was determined by the 32P-postlabelling method. Cells enriched in G1, S 
and G2/M  that were exposed to BaP for 12 h showed different levels of DNA adducts (Figure 2A). 
Levels of adducts in the S- and G2/M-enriched cultures were 3 to 4-fold higher than levels observed in 
G1-enriched cultures.  
 When cells were treated with BPDE for 12 h, the reactive metabolite of BaP, similar levels of 
DNA adducts were formed in all cultures regardless of cell-cycle phase (Figure 2B). Since BPDE 
does not require metabolic activation to bind to DNA, and has a short half-life in aqueous 
environments, this result suggests that the differences observed with BaP are the consequence of 
different capacities to metabolically activate BaP at different stages of the cell cycle. 
 
BaP-induced gene expression changes by microarray analysis 
cDNA microarray analysis was carried out on synchronised cultures of MCF-7 cells enriched in G1, S 
and G2/M  phases and exposed to 2.5 µM BaP for 12 h. 
 Condition clustering and principal component analysis (PCA) revealed that exposure to BaP 
resulted in expression profiles more distinguishable by cell-cycle phase than by treatment (Figure 3). 
Differentially expressed genes in each enriched culture were identified using Student’s t-test and a cut-
off of 1.5-fold change in expression. This resulted in 417 genes in G1-, 189 genes in S-, and 519 genes 
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in G2/M-enriched cultures (Figure 4). 16 genes were shared between all phases (Additional file 2), 11 
between G1 and S only (Additional file 3), 37 between G1 and G2/M only (Additional file 4), and 32 
between S and G2/M only (Additional file 5). However, the majority of modulated genes were cell-
cycle specific (Figure 4).  
 
Functional annotations of BaP-modulated genes 
In order to find biological processes significantly over-represented in the gene lists generated by 
statistical analysis, overlay of gene ontology information was carried out using the Gene Ontology 
(GO) function within GeneSpring. Biological themes that occurred in response to BaP through the cell 
cycle were thereby identified. The majority of functions identified indicate that the transcriptional 
response to BaP in MCF-7 cells in different phases is complex, with a large number of biochemical 
and molecular pathways being affected (Table 1).  
 In G1, genes involved in macromolecule metabolism were over-represented by four functional 
groups: macromolecule biosynthesis (10%), positive regulation of metabolism (5%) and transcription 
(4%), and amino acid transport (2%). These genes are involved in RNA transcription and protein 
synthesis and code for several ribosomal proteins (for example RPS10, RPS14, and RPS15A), solute 
carriers (SLC6A6, SLC7A11 and SLC6A14), and regulators of transcription (ATF4, JUN, EGR1, RSF 
and TRERF1). Other modulated genes belonged to cell differentiation (11%) and cell proliferation 
(8%) functional groups.  
 In S-phase, cell proliferation functional groups (7%) were again identified including the genes 
BTG2, BTG3, GAS8 and HDAC4.  Of these, BTG2 and BTG3 (both up-regulated) belong to a family of 
anti-proliferative genes. Genes involved in PAH metabolism were also over-represented and these 
included CYP1B1, AKR1C1, ALDH1A3 and UGT1A6.  
 In G2/M-phase, the largest functional groups identified were regulation of nucleic acid 
metabolism (24%) and regulation of transcription (22%), followed by cell differentiation (10%) and 
cell cycle (10%). Cell cycle regulation genes induced by BaP included NPM1, NBN, FHIT, CABLES2, 
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ATF5, PCAF, CCNG1, RGC32, SESN1 and BAX. Signal transduction genes were represented by 
several functional groups such as small GTPase-mediated signal transduction (6%), MAPKKK 
cascade (3%) and stress-related protein kinase signalling pathway (2%).  
 
Pathway analysis of BaP-modulated genes 
The generated gene lists from GeneSpring were submitted to Ingenuity Pathway Analysis (IPA) and 
several interesting pathways and genes were revealed. Seven selected networks are presented here 
(Figure 5, 6 and 7 with Additional file 6); they are the top two scoring networks in each enriched 
culture and a third one for G2/M-enriched cultures. This selection was based on the ranking score 
within IPA, where networks with the highest number of significant changes rank highest in the list (a 
list of the top five scoring networks in each enriched culture is presented as supplementary data in 
Additional file7). Several biological processes and signalling pathways were shown to be at the centre 
of BaP-modulation, as described below. 
G1-phase (Figure 5, Network A and B) 
Network 5A relates to the Catenin/Wnt pathway, which has a crucial role in embryonic development. 
Its deregulation can induce disease, most importantly cancer. One important gene in this pathway is 
CTNNB1, which stabilises β-catenin, a cytoplasmic protein that translocates into the nucleus and 
activates downstream genes such as MYC and cyclin D1, both of which regulate cell proliferation [14].  
Network 5B involves mainly the JUN, EGR1 and ERK pathway. JUN, which is up-regulated 
in both G1- and S-phases, is an oncogene and a transcription factor that plays a role in the regulation 
of normal cell cycle progression [15]. EGR1 is another transcription factor that was up-regulated at the 
mRNA level in our study. It is at the crossroads of many signalling cascades. Many functions have 
been attributed to this protein, in particular its involvement in the control of cell growth, survival and 
transformation [16]. 
S-phase (Figure 6, Network A and B) 
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JUN is again the focus of Network 6A and it is linked to several other genes, for example GDF15 and 
ATF3, both of which were up-regulated in the present study. 
ATF3 is a member of the ATF/cyclic AMP response element-binding family of transcription 
factors. It has been proposed that it has a dichotomous role in cancer development by promoting or 
suppressing apoptosis and proliferation [17]. GDF15 is a member of the transforming growth factor B 
(TGFB) superfamily that regulates tissue differentiation and maintenance. It is also a transcriptional 
target of p53 [18]. Another interesting gene shown in this network is NFκB, which promotes cell 
survival. 
Network 6B shows mainly molecules that are involved in oxidative stress; NFE2L2 (NRF2) is 
induced in response to reactive oxygen species such as hydrogen peroxide. NRF2 plays a major role in 
the protective mechanism against xenobiotics capable of damaging DNA and initiating carcinogenesis. 
It is a cellular sensor of chemical- and radiation-induced oxidative and electrophilic stress, and a 
nuclear transcription factor that controls the expression and coordinated induction of a battery of 
defensive genes encoding detoxifying enzymes and antioxidant proteins. One of these proteins is 
NQO1 [19], which is mentioned in the Introduction. 
G2/M-phase (Figure 7, Network A, B and C) 
Network 7A involves two pathways, Akt and apoptosis. Akt is a serine/threonine protein kinase that, 
when activated, plays a key role in mediating signals for cell growth, cell survival (anti-apoptotic), 
cell-cycle progression, differentiation, transcription, translation, and glucose metabolism. Recent 
advances in studying Akt signalling have uncovered important roles in G2/M transition of the cell 
cycle where Akt activity is highest [20].  The NRF2 pathway is again central to Network 7B, which 
shows several genes involved in oxidative stress mechanisms such as NFE2L2, GSTM1, SLC7A11, 
and AHRR. 
Network 7C was selected to be shown here because it has the important tumour suppressor 
TP53 at its centre along with several of its targets, confirming results obtained by gene ontology 
analysis. ASPM participates in the normal mitotic spindle function while MBNL2 belongs to the 
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muscleblind family that regulates alternative splicing. CABLES2 is a pro-apoptotic factor involved in 
p53-dependent or p53-independent apoptosis [21] while Scaper is a cyclin A-interacting protein that 
regulates cell cycle progression at the G/S and G2/M checkpoints [22]. 
 
BaP-induced gene expression changes by RT-PCR 
RT-PCR is a more sensitive and specific measure of gene expression and was used to validate a 
number of key expression changes and to determine the reliability of the microarrays. Genes were 
selected for RT-PCR validation on the basis of: a) GeneSpring statistical analysis, b) gene ontology 
analysis and c) pathway analysis. 
 Genes validated by RT-PCR are shown in Table 2. In the majority of cases there was a good 
correlation between RT-PCR and microarray results, RT-PCR being more sensitive; expression ratios 
were generally underestimated by microarray analysis. For CYP1A1, the correlation between the two 
methods was very low; no clear change in this transcript was evident from the microarrays, whereas 
RT-PCR identified strong induction in all phases ranging from 74-fold in G2/M-enriched cultures to 
over 1800-fold in S-enriched cultures (Figure 8). The failure of the microarrays to identify this gene 
expression change may be a result of very low basal levels of this transcript in this cell line, such that 
even if strongly induced, the microarrays are not sensitive enough to detect it. Another explanation 
could be the quality and specificity of the probe sequence in the array. 
  
Protein expression 
There was a clear induction of both CYP1A1 and CYP1B1 proteins after BaP exposure in all phases, 
but to a greater extent in S- and G2/M- than in G1-enriched cultures (Figure 9). Band quantification 
showed that there was a 1.5-fold higher level of CYP1B1 in S- and G2/M- than in G1-enriched 
cultures after BaP treatment. Similarly, the amount of CYP1A1 protein after BaP exposure was 5 to 6-
fold higher in S- and G2/M- than in G1-enriched cultures. These findings correlate strongly with levels 
of DNA adducts seen in the different phases. There was a down-regulation of AHR after BaP 
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treatment, as the protein levels were lower by 2-fold in BaP-treated compared to DMSO control cells 
in all enriched cultures. 
A number of TP53-regulated genes were modulated in response to BaP exposure at: a) the 
microarray level: STMN1 in G1 only; GDF15 and BTG2 in S only; PCAF, BAX, SESN1, ASPM, 
MBNL2, CABLES2 and Scaper in G2/M only; c-Jun and BTG3 in G1 and S; HINT1 and RGC32 in G1 
and G2/M; b) the RT-PCR level: CDKN1A, GDF15, and RGC32 in all phases. Other genes that 
regulate TP53 activity, such as MDM4 and NPM1, were also modulated by BaP. 
 However, as expected, induction of TP53 gene expression was not observed on the 
microarrays and this was confirmed by RT-PCR. Therefore, p53 protein levels were assessed by 
Western blotting in order to confirm accumulation of this tumour suppressor in response to the BaP in 
different phases of the cell cycle (Figure 9). An increase in p53 protein was observed in MCF-7 cells 
after exposure to BaP in all phases with considerably more protein in G2/M-enriched cultures, 
underlying its significant role in the G2/M checkpoint. These profiles of p53 protein activation are 
similar to those of its direct target CDKN1A (p21), except that there was no induction in S-enriched 
cultures (Figure 9). 
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Discussion 
Microarray technology is a powerful tool for identifying gene expression patterns that are reflective of 
the response of cells to carcinogen exposure [23-25], and can be informative of mechanisms of action 
[26, 27]. Using this technology we have investigated whether human cells are more susceptible to the 
environmental carcinogen BaP at particular phases of the cell cycle and, if so, to elucidate the 
mechanisms involved. The resulting gene expression profiles were related to other phenotypic 
measures of BaP exposure such as DNA damage and cell cycle distribution to further our biological 
understanding of BaP carcinogenesis. 
We found that BaP induced more DNA damage in synchronised MCF-7 cells enriched in S- 
and G2/M-phases than in G1, which indicates that BaP is metabolised with varying efficiency at 
different stages of the cell cycle. This conclusion is supported by the fact that DNA damage induced 
by BPDE -which modifies DNA without further metabolism-, was not cell cycle dependent. Gene 
expression profiling data (mRNA) and protein expression of xenobiotic metabolising enzymes further 
supported this hypothesis. Indeed, CYP1A1 mRNA measured by RT-PCR was almost 20-fold higher 
in S-phase than in G1 and G2/M. CYP1B1 mRNA followed the same pattern with a 2-fold higher 
induction in S-phase. Moreover, comparison between the levels of CYP1A1 in different phases 
revealed more mRNA in S- and G2/M-enriched cultures. The same pattern was observed at the protein 
level for CYP1A1 and CYP1B1. These findings correlate well with the levels of BaP-DNA adducts at 
each phase of the cell cycle, consistent with the role of CYP1A1 and CYP1B1 in the metabolic 
activation of BaP to BPDE. 
Previously, Jiao et al. [11] reported an up-regulation of CYP1A1 mRNA of >100-fold in BaP-
treated S-enriched MCF-7 cultures, while up-regulation in G1- and G2/M-enriched cultures occurred 
to a significantly lesser extent. Consistent with this, they also reported higher levels of DNA damage 
in the form of DNA single strand breaks and BaP-DNA adducts in S-enriched cultures. However, it is 
not the extent of induction that matters but the actual levels (absolute amounts) of mRNA and protein, 
because an apparently very strong induction could be due simply to very low basal levels. Moreover, 
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Jiao and coworkers’ BaP treatment was for 24 h, a duration that is long enough for the cells to 
progress to another phase of the cell cycle. In another study, Santini et al. [13] showed that within 3 h 
of TCDD exposure late G1/early S-phase U937 human leukaemic monocyte lymphoma cells had 1.4- 
and 3-fold higher CYP1A1 mRNA levels than asynchronous/early G1 and G2/M cultures, respectively. 
In contrast, we found that the absolute mRNA levels of CYP1A1 and the protein levels of both 
CYP1A1 and CYP1B1 were actually higher in S- and G2/M-enriched cultures. AHR down-regulation 
at the protein level in all enriched cultures was the result of suppressing AHR signalling by rapid 
proteosomal degradation. Ligand-dependent receptor activation is well established, and several 
mechanisms capable of suppressing prolonged AHR signalling have been identified. These include 
rapid receptor degradation, the action of an AHR Repressor protein (AHRR), and agonist depletion 
through an enzymatic negative feedback loop [28]. AHR activation independent of agonist binding in 
mammalian systems has been proposed, but evidence for it is not yet conclusive. Chang and Puga [29] 
reported that AHR-dependent effects on cell proliferation could be dissociated from exogenous ligand 
binding. In another study, cell density, but not cell cycle, was shown to influence the intracellular 
distribution of AHR [30].  However, neither study established the absence of an endogenous ligand 
responsible for receptor activity. 
Preliminary experiments have indicated that there are no differences in BaP-DNA adduct 
formation between G0- and G1-enriched MCF-7 cultures (data not shown). Therefore, adduct levels in 
G0- are lower than S- and G2/M-enriched cultures. G0 cells are quiescent i.e. not cycling, as is the 
case with many cell types in mammalian tissues. Interpreting the adduct data in the light of this 
information could point to a difference in susceptibility to genotoxic carcinogens between proliferating 
(cycling cells that go beyond G1 to S, and G2/M) and non-proliferating cells (mainly in G0).  
BaP exposure resulted in an arrest of the cells in S-phase of the cell cycle in S- and G2/M-
enriched cultures, indicating that interruption of DNA synthesis had occurred. This is in agreement 
with other studies that have shown the inhibition of DNA synthesis in response to BaP [9, 31]. The 
pause in DNA synthesis is probably due to the intra-S checkpoint, which allows repair enzymes time 
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to recognize the damaged DNA and to correct it, avoiding irreversible errors during replication (i.e. 
mutations). Alternatively, a permanent growth arrest or apoptosis can be initiated if damage is too 
great or persists for too long [32].  
            We found that BaP did not activate the G1/S checkpoint despite p53 and p21 protein induction 
in these phases. The G1 arrest delays DNA damaged cells from progressing through the cell cycle, 
avoiding accumulation of mutations and chromosomal aberrations by means of DNA repair or 
apoptosis. TP53 and its transcriptional target CDKN1A (p21) contribute to G1 and G2 arrest in 
response to DNA damage to maintain genomic stability [33]. These responses consist of the 
ATM(ATR)/CHK2(CHK1)-p53/MDM2-p21 pathway, which is capable of sustaining G1 arrest. 
Phosphorylation of p53 transcription factor and MDM2 (which normally binds to p53 and ensures 
rapid p53 turnover) results in p53 stabilisation and accumulation. p21, in turn, inhibits cyclin 
E(A)/CDK2 and preserves the RB/E2F pathway in its active, growth-suppressing mode [32, 34, 35].  
          In one study, Khan and Dipple [7] showed that following treatment with a range of agents, 
including metabolites of BaP, G1 arrest does not occur in MCF-7 cells and other cell lines. They also 
demonstrated that BPDE is not effective in arresting MCF-7 cells in G1 in spite of inducing dose-
dependent increases in p53 and p21 [36]. The ability of carcinogens to induce cells to evade the G1 
DNA-damage checkpoint and progress into S-phase is known as the stealth property. This property 
presumably enhances the mutation frequency and increases the likelihood of malignant changes. 
           In another study, Jiao et al. [37] investigated the mechanisms by which BaP accelerates cell 
cycle progression (G1/S transition) and induces cell proliferation in human embryo lung fibroblasts. 
They also found that c-Jun activation (by phosphorylation) by p53-dependent PI-3K/Akt/ERK 
pathway might be responsible for BaP-induced cell cycle alterations. Interestingly, JUN mRNA was 
up-regulated by BaP in our study in both G1- and S-enriched cultures. In addition to that, our pathway 
analysis showed it to be significantly involved in Network 5B (G1-enriched cells) and Network 6A 
(S-enriched cells).  
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Gene Ontology analysis revealed several over-represented biological themes after BaP 
exposure. These include cell differentiation, cell proliferation, cell cycle regulation and xenobiotic 
metabolism.  In G1-enriched cultures, some modulated genes belonged to cell differentiation (11%) 
and cell proliferation (8%) functional groups. One of these genes is BTG3 (up-regulated), which has 
been identified as a DNA damage-inducible CHK1-modulated gene. As it is a direct p53 target this 
emphasises its importance in cell cycle regulation and in maintaining genome stability [38]. Another 
example of modulated genes involved in regulating cell proliferation and differentiation is EGR1, 
which was also revealed by pathway analysis (Network 5B in G1-enriched cells). Modulation of the 
expression of this gene was validated by RT-PCR and it was shown to be induced in G1-, and S-
enriched cultures.  Several xenobiotic metabolism genes were also modulated by BaP, including 
CYP1B1, GSTT2 and NQO1. Detoxification of PAH quinone metabolites is carried out by 
NAD(P)H:quinone oxidoreductase encoded by NQO1 [39], which is also required for p53 stabilisation 
in response to DNA damage [40]. Glutathione S-transferase T2 (GSTT2) is involved in cellular 
defence against toxic and carcinogenic electrophilic compounds by conjugation of reduced glutathione 
to hydrophobic electrophiles [41], so it was a logical finding that GSTT2 was up-regulated in response 
to BaP exposure.  
           Pathway analysis revealed the activation of the Catenin/Wnt pathway (Network 5A) in the 
response to BaP exposure. Consistent with this, RT-PCR analysis showed that DKK1 (a Wnt 
antagonist) was down-regulated (by 7-fold) in G1-enriched cultures and CTNNB1 was up-regulated 
(by 1.4-fold) in the same cultures.  
In S-phase, cell proliferation and apoptosis genes such as BTG2 and HDAC4 were also 
differentially expressed. Previously, our team showed that BTG2 was up-regulated by BaP and BPDE 
at different time points in MCF-7 cells [9, 10]. Its expression was also shown to be induced by 
genotoxic stress through a p53-dependent mechanism [42]. HDAC4, which encodes a histone 
deacetylase that represses transcription and regulates differentiation, was down-regulated in our 
experiments [43]. Differentially expressed genes involved in PAH metabolism included CYP1B1, 
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AKR1C1, ALDH1A3 and UGT1A6. CYP1B1 (also induced in G1- and G2/M-enriched cultures) 
encodes a member of the CYP superfamily of monooxygenases and is involved in the metabolic 
activation of BaP [44, 45].  Interestingly, enhanced expression of this enzyme has been observed in a 
number of cancers [46, 47] and it has been demonstrated, in experiments involving CYP1B1-null 
mice, that it enhances the carcinogenicity of 7,12-dimethylbenz[a]anthracene [48]. CYP1B1 has also 
been found to be up-regulated in primary human mammary epithelial cells exposed to BaP, 
highlighting the importance of this enzyme in BaP metabolism in this tissue [49]. Consistent with 
previous studies [9, 50], AKR1C1 was also found to be up-regulated by BaP. It encodes an aldo-keto 
reductase capable of metabolising PAH trans-dihydrodiols to o-quinones that can lead to the formation 
of DNA adducts and reactive oxygen species (ROS) [50, 51], thus providing another pathway of PAH 
genotoxicity. UGT1A6 is involved in glucuronidation, which is a major pathway for detoxification of 
PAH metabolites [52].  
Another interesting gene function category revealed by the transcriptomic analysis was that of 
DNA-damage induced protein phosphorylation, as exemplified by MAP2K6. This gene encodes a 
member of the dual specificity protein kinase family, which functions as a mitogen-activated protein 
(MAP) kinase kinase. MAP kinases, also known as extracellular signal-regulated kinases (ERKs), act 
as an integration point for multiple biochemical signals. This protein phosphorylates and activates p38 
MAP kinase in response to inflammatory cytokines or environmental stress. As an essential 
component of the p38 MAP kinase signal transduction pathway, MAP2K6 is involved in many cellular 
processes such as stress-induced cell cycle arrest, transcription activation and apoptosis [53]. 
In G2/M–phase, BaP altered the expression of several cell cycle regulation genes, including 
NPM1, PCAF, NBN, RGC32, SESN1 and BAX as shown by Gene Ontology and pathway analysis 
(Table 1 and Network 7C). NPM1 (up-regulated) has been shown to be implicated in human 
tumourigenesis, functioning both as an oncogene and as a tumour-suppressor. It is involved in many 
pathways such as cell cycle control, DNA repair and apoptotic response to stress by modulating the 
activity and stability of critical tumour-suppressor proteins such as p53 [54]. NBN (up-regulated) is 
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involved in cell cycle checkpoints in response to DNA damage [55]. RGC32, SESN1 and BAX (all up-
regulated) are all targets of p53 contributing to its role in cell cycle regulation, metabolism and 
apoptosis [56-58]. Indeed, accumulation of p53 was seen after BaP treatment by Western blotting 
(Figure 9). 
 
Conclusions 
Exposure of synchronized MCF-7 cells to BaP has identified a complex gene expression response by 
microarray analysis.  A number of genes were found to have their expression altered by BaP, including 
those involved in xenobiotic metabolism, apoptosis, cell cycle regulation and DNA repair. Gene 
ontology and pathway analysis showed the involvement of various signalling pathways in the response 
to BaP, such as Catenin/Wnt pathway in G1, ERK pathway in G1 and S, Nrf2 pathway in S and G2/M 
and Akt pathway in G2/M.  
             A key finding in this study was that higher levels of DNA adducts in S- and G2/M-enriched 
cultures correlated with higher levels of CYP1A1 and CYP1B1 mRNA and protein expression, 
indicating that proliferating cells are more prone to DNA damage by genotoxic stress than non-
proliferating cells. Our results clearly demonstrate that this is due to the varying efficiency of BaP 
metabolism through the cell cycle.  Additional studies with other cells lines and genotoxic agents will 
be required to determine whether our findings, in terms of adduct formation and expression of 
CYP1A1 and CYP1B1 (both at the mRNA and protein level) are universal or specific to certain cell 
types. 
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Materials and Methods 
Cell culture and treatment 
MCF-7 human breast carcinoma cells were purchased from the European Collection of Cell Cultures 
(ECACC, Salisbury, UK). Cells were grown as adherent monolayers and maintained in Dulbecco’s 
modified Eagle’s medium with GlutamaxTM  I, 1000 mg/L D-glucose and sodium pyruvate (Invitrogen, 
Paisley, UK) and supplemented with 10% heat-inactivated foetal bovine serum (Invitrogen) and 100 
U/mL penicillin and 100 µg/mL streptomycin (Sigma-Aldrich, Dorset, UK). Cells were incubated in a 
humidified 5% CO2 atmosphere at 37oC and sub-cultured every 72 h when the cells were 80% 
confluent.  
Culture conditions were manipulated in order to generate (1) G0/G1-enriched cultures by 
serum deprivation for 48 h (cells were kept in G0 by not adding the serum back during the BaP 
treatement in contrast to G1-enriched cells); (2) S-enriched cultures by serum deprivation for 48 h 
followed by 18 h growth in complete media; and (3) G2/M-enriched cultures by treatment for 24 h 
with 1 µg/mL aphidicolin followed by 0.25 µM colchicine for 12 h. Cell cycle distributions, 
determined by flow cytometry  are shown in Table 3.   
Cells were seeded at 2 × 105 cells/ml and treated with BaP (2.5 µM), and BPDE (0.5 µM) for 
12 hours. DMSO only was added to control cultures and its volume was kept at 0.3% of the total 
culture volume. Cells were harvested by trypsinisation followed by washing with PBS. All cell 
incubations for the different experimental applications were carried out in duplicate or triplicate. 
 
Flow cytometry 
Harvested cells were re-suspended in 0.2 mL 10X PBS solution and fixed in 2 mL of ice-cold 70% 
ethanol. Samples were then stored at −200C overnight. Twenty four hours prior to flow cytometry 
analysis, samples were centrifuged at 1500 × g for 5 minutes and resuspended in staining buffer 
containing 40 µg/mL propidium iodide (Invitrogen), 100 µg/mL RNase (Qiagen, UK) in PBS buffer at 
a final density of 1 × 106 cells/mL. Cells were then incubated at 370C for 60 minutes and stored at 40C 
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overnight. The DNA content of 10,000 events per sample was analysed using a Beckman Coulter 
EPICS Elite ESP (Beckman Coulter, Buckinghamshire, UK) at 488 nm. The percentage of cells in 
each phase of the cell cycle was determined using Cylchred v1.0.2 and WinMDI v2.8 software [59]. 
Differences between control and treated cells were examined for statistical significance using 
Student’s t-test (two-tailed). 
 
Cell viability  
Cell viability (% control) was determined by cell counting with the CASY Model TT Electronic Cell 
Analyser (Innovatis AG, Germany).  
 
DNA adduct analysis 
DNA was isolated from cell pellets by a standard phenol chloroform extraction method. DNA was 
quantified spectrophotometrically and DNA adducts were determined for each DNA sample using the 
nuclease P1 enrichment version of 32P-postlabelling method [60]. Briefly, DNA samples (4 µg) were 
digested with micrococcal nuclease (120 mU, Sigma, UK) and calf spleen phosphodiesterase (40 mU, 
Calbiochem, UK), then enriched and labelled as reported. Solvent conditions for the resolution of 32P-
labelled adducts on polyethyleneimine-cellulose thin-layer chromatography (TLC) were as described 
[9]. After chromatography TLC plates were scanned using a Packard Instant Imager (Dowers Grove, 
IL, USA) and DNA adduct levels (RAL, relative adduct labelling) were calculated from the adduct 
cpm, the specific activity of [γ-32P]ATP and the amount of DNA (pmol of DNA-P) used. Results were 
expressed as DNA adducts/108 nucleotides. An external BPDE-DNA standard [61] was employed for 
identification of adducts in experimental samples.  
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RNA isolation and whole-genome gene expression profiling 
Total RNA was extracted from cells using the Qiagen RNeasy Mini Kit protocol (RNeasy Mini 
Handbook, Qiagen, UK). RNA was quantified spectrophotometrically, and integrity was determined 
using a 2100 Bioanalyser (Agilent Technologies, UK). Only RNA with an integrity number ≥ 9 was 
used for gene expression analysis.  
Gene expression analysis was carried out using the Agilent two-colour microarray-based gene 
expression analysis (Agilent Technologies, UK), which uses cyanine 3 (Cy3)- and cyanine 5 (Cy5)-
labelled targets to measure gene expression in experimental and control samples.  
Agilent Human 4 × 44K Genome-wide arrays were used and the reference design was applied, 
whereby a Universal Human Reference RNA (Stratagene, La Jolla, USA) was hybridised to every 
sample.  Cy3-(sample)- and Cy5-(reference)-labelled probes were hybridised to the oligo microarrays 
using the Gene Expression Hybridization Kit (Agilent Technologies, UK) using Agilent SureHyb 
chambers for 17 hours in Rotisserie Hyb Oven set to 65ºC (Agilent) and rotating at 10 rpm. The array 
slides were washed according to the manufacturer’s instructions (Agilent) and dried with compressed 
air prior to scanning on an Axon B400 Scanner (Axon, Instruments, USA). 
 
Microarray data analysis 
The multi-image TIFF files generated by the scanner were exported to BlueFuse software, which 
adjusts the initial grid position and optimises spot finding in the image automatically so that each spot 
on the array is assigned a specific gene. BlueFuse software generated Excel files, which were analysed 
using GeneSpring v7.2 software (Silicon Genetics). 
Data were imported into GeneSpring software and subjected to Per chip and Per spot lowess 
normalisation. Bad spots that were flagged in BlueFuse software were filtered out in order to give a 
gene list of reliable data. Cy3/Cy5 ratios of the 3 biological replicates were averaged and then used to 
identify modulated genes using 1 Way-ANOVA with a cut-off of 1.5-fold change and a Student’s t-
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test p-value of less than 0.05. Over-representation analysis of differentially expressed genes was 
carried out using the Gene Ontology function within GeneSpring and Ingenuity pathway software. 
The gene expression data discussed in this publication have been deposited in NCBI Gene Expression 
Omnibus [62] and are accessible through GEO Series accession number GSE26917. 
 
Real-time quantitative PCR 
Two-step reverse transcription-PCR was used to generate cDNA for relative quantitation analysis 
using real-time fluorescent PCR. cDNA was reversed transcribed from 1 µg total RNA using random 
primers following the Superscript III Reverse Transcriptase First-Strand cDNA Synthesis Protocol 
(Invitrogen). cDNA was diluted 1:10 and 2 µL was used as template to perform RT-PCR in a 15 µL 
reaction. GAPDH was used as an endogenous control (Applied Biosystems, UK) in multiplexed PCR 
reactions on an ABI PRISM 7900HT Sequence Detection System (Applied Biosystems) with standard 
thermocycling conditions (50°C 2 min, 95°C 10 min, then 40 cycles of 95°C 15 s, 60°C 1 min), using 
Taqman Universal PCR Master Mix (Applied Biosystems). To confirm the modulated expression of 
the selected target genes, 20x Assays-On-Demand™ gene expression primers and probes (Applied 
Biosystems) were used. The list of the assays is provided as Additional file 8. Relative gene 
expression between the control (or calibrator) and treated samples was calculated after normalisation 
to the GAPDH reference using the comparative threshold cycle (CT) method. 
 
Western blot analysis 
Cells were lysed in 800 µL lysis buffer (62.5 mM Tris pH 6.8, 1 mM EDTA pH 8.0, 2% SDS, 10% 
Glycerol). Samples were sonicated to break up the DNA and their protein concentration was 
determined using the BCA assay (Piercenet, UK) in order to load the same amounts of protein. Cell 
lysates were electrophoretically separated using Criterion XT 4–12% Bis-Tris gels (Bio-Rad, UK). 
Following electrophoresis, gels were transferred onto a nitrocellulose membrane (Millipore, UK). 
Ponceau staining was performed to check for the quality of transfer, and then the membranes were 
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blocked by incubation in 5% non-fat dry milk dissolved in TBST overnight at 4°C. Blots were then 
incubated with primary antibody, thereafter with the species-specific horseradish peroxidase-
conjugated secondary antibody and bands detected by chemiluminescence (ECL detection reagents, 
GE Healthcare). The following primary antibodies were purchases: anti-p53 (Ab-6; 1:2,000) from 
Calbiochem (Darmstadt, Germany), anti-p21 (BD 556431; 1:2,000) from BD Science (Oxford, UK), 
anti-CYP1B1 (CYP1B11-A; 1:2,000) from Alpha Diagnostic (Hampshire, UK), anti-AHR (Abcam 
ab2770; 1:1,000). Anti-CYP1A1 raised in rabbits against purified human recombinant CYP1A1 was a 
generous gift from F. Peter Guengerich (Vanderbilt University, USA) and was diluted 1:4,000. The 
antibody to detect β-actin (Ab6276; 1:25,000) was purchased from Abcam and used as a loading 
control. Two secondary horseradish peroxidise-linked antibodies were purchased: anti-mouse (CST 
7076; 1:10,000), anti-rabbit (CST 7074; 1:10,000) from Cell Signalling Technologies (Herts, UK). 
Band quantification was carried out using ImageJ software [63]. 
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Legends of figures 
Figure 1. BaP delays escape from S-phase. A- MCF-7 cells were synchronised in G0/G1-phase by 
serum-deprivation for 48 hours, after which cells were exposed for 12 h to BaP (2.5 µM) or DMSO. 
B- MCF-7 cells were enriched in S-phase by serum-deprivation for 48 h, then left to grow for 18 h, 
after which they were treated by either BaP (2.5 µM) or DMSO for 12 h. C- MCF-7 cells were 
synchronised in G2/M-phase by exposing them to aphidicolin (1 µg/mL) for 24 h followed by 
colchicine (0.25 µM) for 12 h. Subsequently, they were released into media containing either BaP (2.5 
µM) or DMSO for 12 h. Cell cycle distribution was examined by flow cytometry. The profiles are 
representative of three independent experiments. 
 
Figure 2. DNA adduct levels in synchronised MCF-7 cells. Cell were synchronised in G0/G1, S and 
G2/M  phases with different methods, after which they were exposed to 2.5 µM BaP or 0.5 µM  BPDE 
for 12 h. DNA was isolated with a standard phenol/chloroform method and DNA adducts were 
assessed by the 32P-postlabelling method. Results were expressed as DNA adducts/108 nucleotides. 
 
Figure 3. Cell cycle effects on microarray results. A- Hierarchical clustering of genes in different 
conditions; B- Principal component analysis (PCA). Both methods were performed in GeneSpring on 
a list of genes that had good confidence measurement and revealed a cell cycle response in gene 
expression profiles. Before BaP (2.5 µM) treatment for 12 h, MCF-7 cells were synchronised in 
different phases of the cell cycle. In hierarchical clustering (A), red colour denotes up-regulation and 
green denotes down-regulation. In PCA analysis (B), squares with black dots denote BaP-treated 
samples. 
 
Figure 4. Venn diagram of the gene lists in different phases. Only genes that exhibited 1.5-fold or 
greater change after BaP treatment are shown. The gene lists represent expression profiles of MCF-7 
cells synchronised in different phases of the cell cycle. Although there was overlap of the expression 
profiles between the phases, the majority of the changes were cell-cycle dependent. 
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Figure 5. Ingenuity Pathway Analysis (IPA) on genes modulated by BaP in G1-enriched MCF7 
cell cultures. Gene lists of 1.5-fold differentially expressed genes in different phases were imported to 
IPA software, which revealed the involvement of several pathways and genes in the response to BaP. 
Two networks are shown here. Red colour denotes up-regulation and green colour denotes down-
regulation. The IPA legend is shown in Additional file 6. 
 
Figure 6. Ingenuity Pathway Analysis (IPA) on genes modulated by BaP in S-enriched MCF-7 
cell cultures. Gene lists of 1.5-fold differentially expressed genes in different phases were imported to 
IPA software, which revealed the involvement of several pathways and genes in the response to BaP. 
Two networks are shown here. Red colour denotes up-regulation and green colour denotes down-
regulation. The IPA legend is shown in Additional file 6. 
 
Figure 7. Ingenuity Pathway Analysis (IPA) on genes modulated by BaP in G2/M-enriched 
MCF-7 cell cultures. Gene lists of 1.5-fold differentially expressed genes in different phases were 
imported to IPA software, which revealed the involvement of several pathways and genes in the 
response to BaP. Three networks are shown here. Red colour denotes up-regulation and green colour 
denotes down-regulation. The IPA legend is shown in Additional file 6. 
 
Figure 8. Relative CYP1A1 mRNA expression levels in synchronised MCF7 cells with and 
without BaP treatment. mRNA quantification was carried out by RT-PCR. The highest expressed 
sample in the RT-PCR was set to 100% and other samples’ expressions are shown relative to that. 
Values represent mean ± SD from 3 determinations.  
 
Figure 9. Expression of CYP1A1, CYP1B1, AHR, p53, and p21 protein levels in MCF7 cells in 
different phases of the cell cycle in response to BaP detected by Western blots. Cells were treated 
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with DMSO (0.3%) or BaP (2.5 µM) for 12 h. 15 µg protein was loaded in each lane. β-actin was used 
as a loading control.  
 
 
29 
 
Tables 
Table 1: Biological processes significantly affected (p<0.05) and over-represented after BaP 
treatment in synchronised MCF-7 cells in G0/G1, S, and G2/M as determined by Gene Ontology 
(GO) analysis within GeneSpring software. Genes over-represented had an expression change of at 
least 1.5-fold. 
Biological Process % of Genes in List p-Value 
G1-enriched cells 
GO:7275: development 26.4 1.50E-03 
GO:9653: morphogenesis 11.8 1.60E-02 
GO:30154: cell differentiation 11.4 1.20E-02 
GO:9059: macromolecule biosynthesis 10 1.10E-02 
GO:8283: cell proliferation 8.6 1.90E-02 
GO:31325: positive regulation of cellular metabolism 5 3.10E-02 
GO:45941: positive regulation of transcription 4.1 4.90E-02 
GO:45321: immune cell activation 3.2 2.30E-02 
GO:51606: detection of stimulus 2.3 4.00E-03 
S-enriched cells 
GO:50789: regulation of biological process 42.7 1.30E-02 
GO:42127: regulation of cell proliferation 7.3 2.10E-02 
GO:40007: growth 5.5 1.70E-02 
GO:42592: homeostasis 5.5 4.10E-02 
GO:45944: positive regulation of transcription from RNA polymerase II promoter 3.6 2.20E-02 
GO:7420: brain development 2.7 4.60E-02 
GO:9065: glutamine family amino acid catabolism 1.8 7.20E-03 
GO:6805: xenobiotic metabolism 1.8 2.10E-02 
GO:9266: response to temperature stimulus 1.8 2.10E-02 
GO:7157: heterophilic cell adhesion 1.8 2.20E-02 
GO:6664: glycolipid metabolism 1.8 2.70E-02 
GO:30203: glycosaminoglycan metabolism 1.8 5.00E-02 
GO:35026: leading edge cell differentiation 0.9 5.60E-03 
GO:42268: regulation of cytolysis 0.9 5.60E-03 
GO:46399: glucuronate biosynthesis 0.9 1.10E-02 
GO:16264: gap junction assembly 0.9 1.70E-02 
GO:6975: DNA damage induced protein phosphorylation 0.9 1.70E-02 
GO:48246: macrophage chemotaxis 0.9 3.30E-02 
G2/M-enriched cells 
GO:19219: regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism 23.9 1.40E-03 
GO:6355: regulation of transcription, DNA-dependent 21.8 1.80E-02 
GO:30154: cell differentiation 10.6 1.10E-02 
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GO:7049: cell cycle 9.9 2.70E-04 
GO:7264: small GTPase mediated signal transduction 6.3 6.90E-03 
GO:9888: tissue development 4.2 1.30E-02 
GO:16337: cell-cell adhesion 3.5 6.20E-03 
GO:165: MAPKKK cascade 2.8 1.70E-02 
GO:31098: stress-activated protein kinase signaling pathway 1.8 2.30E-03 
GO:8624: induction of apoptosis by extracellular signals 1.4 3.70E-02 
GO:42551: neuron maturation 1.4 3.00E-03 
GO:6986: response to unfolded protein 1.4 1.10E-02 
GO:51259: protein oligomerization 1.4 2.60E-02 
GO:9266: response to temperature stimulus 1.1 1.50E-02 
 
 
 
 
31 
 
Table 2. A summary of gene expression changes induced by BaP in MCF7 cells using microarray 
and RT-PCR analysis. A 1.5-fold cut-off was used.  ↑ denotes up-regulation, and ↓ denotes down-
regulation.  
Change in G1 Change in S Change in G2/M 
Gene 
Symbol Biological function RT-PCR Microarrays RT-PCR Microarrays RT-PCR Microarrays 
CYP1A1 Xenobiotic metabolism ↑ 91.5-fold           ─ ↑ 1866.8-fold          ─ ↑ 73.7-fold           ─ 
CYP1B1 Xenobiotic metabolism ↑ 19-fold ↑ 2.7-fold ↑ 40.4-fold ↑ 3.2-fold ↑ 21.9-fold ↑ 2.3-fold 
GDF15 Cell differentiation ↑ 11.2-fold           ─ ↑ 22.5-fold ↑ 8.9-fold ↑ 2-fold           ─ 
TIPARP PARP family ↑ 5.5-fold ─ ↑ 5.8-fold ↑ 2.9-fold ↑ 6-fold ↑ 4.7-fold 
JUN  Cell proliferation ↑ 5.5-fold ↑ 1.8-fold ↑ 5.1-fold ↑ 3.6-fold           ─           ─ 
p21 cell cycle checkpoints ↑ 3.2-fold ─ ↑ 6.6-fold           ─           ─           ─ 
RASAL1 Ras regulator ↑ 3.4-fold ─ ↑ 2.8-fold ↑ 3.3-fold           ─ ↓ 2.8-fold 
RGC32 Cell cycle control ↑ 2.9-fold ↑ 1.6-fold ↑ 2.3-fold           ─ ↑ 2.3-fold ↑ 1.5-fold 
ALDH1A3 Xenobiotic metabolism ↑ 1.7-fold ─ ↑  4.2-fold ↑  4.3-fold ↑ 2.4-fold           ─ 
DLX2 Development ↑ 1.5-fold ─ ↑  4.8-fold ↑  5-fold ↑ 2.5-fold ↑ 3.3-fold 
CEBPA Mitotic growth arrest ↑ 1.7-fold ─ ─          ─ ↑ 1.5-fold ↑ 1.7-fold 
NRF2 Oxidative stress ↑ 1.5-fold ─ ─          ─ ↑ 1.6-fold ↑ 1.6-fold 
ATF3 Transcription Factor  ↑ 3-fold ─ ↑ 6.1-fold ↑ 4.5-fold          ─   
DNAJB4 Oxidative stress ↑ 2.2-fold ─ ↑ 1.6-fold ↑ 1.9-fold          ─ ↑ 1.5-fold 
Bax Apoptosis ↑ 1.5-fold ─ ↑ 1.6-fold          ─          ─ ↑ 1.6-fold 
SPRY4 MAPK signalling ─ ─          ─ ↑ 4.5-fold ↑ 1.7-fold          ─ 
GSTT2 Xenobiotic metabolism ↑ 2.8-fold ↑ 1.7-fold          ─          ─          ─          ─ 
CABLES2 Apoptosis          ─          ─          ─          ─          ─ ↑ 2.3-fold 
PTGER4 T-cell factor signalling          ─ ↑ 2.7-fold ↑ 1.5-fold          ─          ─ ↑ 2.2-fold 
BBC3 Apoptosis          ─          ─ ↑ 2.1-fold ↑ 5-fold          ─ ↑ 1.9-fold 
EGR1 Cell growth and proliferation ↑ 6.7-fold ↑ 2.7-fold ↑ 2.5-fold           ─           ─           ─ 
CTNNB1 Cell adhesion ↑ 1.5-fold ↑ 2.25-fold          ─          ─          ─          ─ 
PLK3 Cell cycle control          ─           ─ ↑ 2.5-fold ↑ 3.4-fold          ─          ─ 
AFF4 Transcription Elongation          ─          ─          ─ ↓ 2.6-fold ↓ 1.5-fold ↓ 6.2-fold 
ZBRK1 DNA damage response          ─          ─          ─ ↓ 4.7-fold          ─          ─ 
DKK1 Wnt/Catenin ↓ 7-fold ↓ 3.1-fold ↓ 2.8-fold          ─ ↓ 2.4-fold          ─ 
KAT2B Transcription regulation ↓ 4.6-fold           ─ ↓ 3-fold          ─ ↓ 6.5-fold ↓ 1.7-fold 
RASGRP1 Ras signalling  ↓ 3.8-fold ↓ 1.5-fold ↓ 2.2-fold          ─ ↓ 6-fold ↓ 2-fold 
JMJD2C Histone demethylase  ↓ 3.6-fold          ─ ↓ 4.5-fold  ↓ 2-fold ↓ 3-fold  ↓ 1.8-fold 
HDAC4 Cell cycle control  ↓ 2.1-fold          ─ ↓ 2.7-fold ↓ 1.8-fold ↓ 1.8-fold          ─ 
FERMT1 Actin cytoskeleton  ↓ 2.1-fold ↓ 6.7-fold ↓ 1.8-fold          ─ ↓ 2.5-fold          ─ 
Scaper cell cycle checkpoints ↓ 1.8-fold ↓ 1.5-fold ↓ 1.8-fold ↓ 2-fold ↓ 2.8-fold ↓ 2.2-fold 
NPM1 Cell proliferation/Apoptosis          ─          ─          ─          ─          ─ ↑ 2.4-fold 
YWHAQ Cell cycle control/Apoptosis          ─          ─          ─          ─          ─          ─ 
AHR Xenobiotic Metabolism          ─          ─          ─          ─          ─          ─ 
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p53 Tumour Suppressor          ─          ─          ─          ─          ─          ─ 
RFC5 Replication Factor          ─ ↑ 1.8-fold          ─          ─          ─          ─ 
Hint1 Apoptosis          ─ ↑ 2.2-fold          ─          ─          ─ ↑ 1.5-fold 
NQO1 Xenobiotic metabolism          ─ ↑ 2.2-fold          ─          ─          ─          ─ 
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Table 3:  Cell cycle distribution of MCF-7 cells prior to BaP treatment. Cells were manipulated to 
generate: G0/G1-, S-, and G2/M-enriched cultures. 
 
Cell cycle distribution (%) 
Culture manipulations (time, h) G0/G1-phase S-phase G2/M-phase 
G0/G1-enriched 48 h serum deprivation 65.3 ± 2.1 14.1 ± 2.4 20.6 ± 2.4 
S-enriched 18 h after 48 h serum deprivation 24.7 ± 4.2 55.7 ± 8.2 19.5 ± 4.0 
G2/M-enriched 12 h colchicine (0.25 µM) after 24 h aphidicolin (1 µg/mL) 8.9 ± 2.2 18.2 ± 4.1 72.9 ± 5.9 
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Figure 8 
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Figure 9 
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Additional files 
Additional file 1. BaP delays escape from S-phase (Histogram representation). A- MCF-7 cells 
were synchronised in G0/G1-phase by serum-deprivation for 48 h, after which cells were exposed for 
12 h to BaP (2.5 µM) or DMSO. B- MCF-7 cells were enriched in S-phase by serum-deprivation for 
48 h, then left to grow for 18 h, after which they were treated by either BaP (2.5 µM) or DMSO for 12 
h. C- MCF-7 cells were synchronised in G2/M-phase by exposing them to aphidicolin (1 µg/mL) for 
24 h followed by colchicine (0.25 µM) for 12 h. Subsequently, they were released into media 
containing either BaP (2.5 µM) or DMSO for 12 h. Cell cycle distribution was examined by flow 
cytometry and DNA histograms were generated. The profiles are representative of three independent 
experiments. 
 
Additional file 2. List of differentially-expressed genes common to G1-, S- and G2/M-enriched 
cultures after 12h BaP (2.5 µM) treatment. Only genes which had a change of 1.5-fold after BaP 
exposure are shown. 
 
Additional file 3. List of differentially-expressed genes common to G1- and S-enriched cultures 
only after 12h BaP (2.5 µM) treatment. Only genes which had a change of 1.5-fold after BaP 
exposure are shown. 
 
Additional file 4. List of differentially-expressed genes common to G1- and G2/M-enriched 
cultures only after 12h BaP (2.5 µM) treatment. Only genes which had a change of 1.5-fold after 
BaP exposure are shown. 
 
Additional file 5. List of differentially-expressed genes common to S- and G2/M-enriched 
cultures only after 12h BaP (2.5 µM) treatment. Only genes which had a change of 1.5-fold after 
BaP exposure are shown. 
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Additional file 6. Ingenuity pathway analysis (IPA) figures legend. 
 
Additional file 7. List of the top five scoring network in each enriched culture. Scores are obtained 
within Ingenuity pathway analysis (IPA) software. 
 
Additional file 8. Gene expression primers and probes used in RT-PCR reactions. The assays 
were purchased from Applied Biosystems and each consists of 2 primers (forward and reverse) and a 
Taqman probe. 
 
 
 
 
 
 
 
